Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

QNCX Quince Therapeutics, Inc.

Not Yet Opened 12-20 16:00:00 EST

1.78

+0.02

+1.14%

盘后1.85

+0.07+3.93%

19:36 EST

High1.85	Low1.74	Vol106.19K
Open1.76	D1 Closing1.76	Amplitude6.08%
Mkt Cap78.32M	Tradable Cap62.90M	Total Shares44.00M
T/O187.79K	T/O Rate0.30%	Tradable Shares35.34M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

{"stockData":{"symbol":"QNCX","market":"US","secType":"STK","nameCN":"Quince Therapeutics, Inc.","latestPrice":1.78,"timestamp":1734728400000,"preClose":1.76,"halted":0,"volume":106191,"hourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.78,"latestTime":"19:36 EST","volume":11116,"amount":19881.5499,"timestamp":1734741361653},"delay":0,"floatShares":35338700,"shares":44001643,"eps":-1.250352,"marketStatus":"Not Yet Opened","change":0.02,"latestTime":"12-20 16:00:00 EST","open":1.76,"high":1.847,"low":1.74,"amount":187790.309458,"amplitude":0.060795,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-1.250352,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Market Trading","tradingStatus":1,"beginTime":1734944400000},"marketStatusCode":0,"adr":0,"listingDate":1557374400000,"exchange":"NASDAQ","adjPreClose":1.76,"preHourTrading":{"tag":"盘前","latestPrice":1.76,"preClose":1.76,"latestTime":"08:33 EST","volume":1096,"amount":1887.609893,"timestamp":1734701631079},"postHourTrading":{"tag":"盘后","latestPrice":1.85,"preClose":1.78,"latestTime":"19:36 EST","volume":11116,"amount":19881.5499,"timestamp":1734741361653},"volumeRatio":0.4769824258432956,"impliedVol":0.9996,"impliedVolPercentile":0.0278},"requestUrl":"/m/hq/s/QNCX/wiki","defaultTab":"wiki","newsList":[{"id":"2492636761","title":"Quince Therapeutics Files Mixed Securities Shelf; Shares Rise After Hours","url":"https://stock-news.laohu8.com/highlight/detail?id=2492636761","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492636761?lang=en_us&edition=fundamental","pubTime":"2024-12-19 06:48","pubTimestamp":1734562082,"startTime":"0","endTime":"0","summary":"Quince Therapeutics  filed a shelf registration statement with the US Securities and Exchange Commission Wednesday covering the potential sale of up to $200 million of securities from time to time in one or more offerings.The statement covers common and preferred stock, debt securities, and warrants.The company said it plans to use any net proceeds generated from the sale of the securities for working capital and general corporate purposes.Quince said it may sell up to $75 million of its common shares from time to time to or through certain agents.The company's shares were up 7.6% in after-hours activity.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","LENZ","QNCX"],"gpt_icon":0},{"id":"2492363152","title":"BRIEF-Quince Therapeutics Files For Mixed Shelf Offering Of Up To $200 Million - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2492363152","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492363152?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:27","pubTimestamp":1734557256,"startTime":"0","endTime":"0","summary":"Dec 18  - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS: FILES FOR MIXED SHELF OFFERING OF UP TO $200 MILLION - SEC FILING   * QUINCE THERAPEUTICS: SALES AGREEMENT PROSPECTUS COVERS OFFERING OF UP TO $75.0 MILLION OF COMMON STOCK THAT MAY BE ISSUED FROM TIME TO TIMESource text:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4008","UP","LENZ","BK4139","QNCX"],"gpt_icon":0},{"id":"2492154873","title":"Quince Therapeutics: Sales Agreement Prospectus Covers Offering of up to $75.0 Mln of Common Stock That May Be Issued From Time to Time","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154873","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154873?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:04","pubTimestamp":1734555874,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ0T7:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2492154808","title":"Quince Therapeutics: Files for Mixed Shelf Offering of up to $200 Mln - SEC Filing","url":"https://stock-news.laohu8.com/highlight/detail?id=2492154808","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492154808?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:04","pubTimestamp":1734555874,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nFWN3NJ0T7:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2492263903","title":"Quince Therapeutics initiated with a Buy at Brookline","url":"https://stock-news.laohu8.com/highlight/detail?id=2492263903","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492263903?lang=en_us&edition=fundamental","pubTime":"2024-12-18 18:00","pubTimestamp":1734516035,"startTime":"0","endTime":"0","summary":"Brookline initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $9 price target Quince is advancing its AIDE technology platform t...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-initiated-with-a-buy-at-brookline?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX","BRKL","BK4211","LENZ","BK4139"],"gpt_icon":0},{"id":"2492745970","title":"Quince Therapeutics: Promising Investment with EryDex’s Innovative Treatment and Strong Financial Position","url":"https://stock-news.laohu8.com/highlight/detail?id=2492745970","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492745970?lang=en_us&edition=fundamental","pubTime":"2024-12-18 17:56","pubTimestamp":1734515770,"startTime":"0","endTime":"0","summary":"Kumaraguru Raja, an analyst from Brookline Capital Markets, has initiated a new Buy rating on Quince Therapeutics (QNCX). Kumaraguru Raja’s rating ...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/blurbs/quince-therapeutics-promising-investment-with-erydexs-innovative-treatment-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/blurbs/quince-therapeutics-promising-investment-with-erydexs-innovative-treatment-and-strong-financial-position?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","QNCX","BK4139"],"gpt_icon":0},{"id":"2483174879","title":"BRIEF-Quince Therapeutics Regains Compliance With Nasdaq Listing Rule","url":"https://stock-news.laohu8.com/highlight/detail?id=2483174879","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483174879?lang=en_us&edition=fundamental","pubTime":"2024-11-14 20:17","pubTimestamp":1731586669,"startTime":"0","endTime":"0","summary":"Nov 14 (Reuters) - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS: REGAINS COMPLIANCE WITH NASDAQ LISTING RULE 5450(A)(1)Source text:  Further company coverage:    ((Reuters.Briefs@thomsonreuters.com;))","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","BK4139","BK4567","NQmain","LENZ","LU2092937221.SGD","BK4121","QID",".IXIC","QLD","A","SQQQ","LU2041044095.USD","IE00BKPKM429.USD","LU1543694498.USD","BK4588","TQQQ","LU2413666699.HKD","NDAQ","LU2095319765.USD","LU2413666426.HKD","BK4112","IE00BGHQF748.EUR","IE00B3QW5Z07.USD","PSQ","LU2210149790.SGD","LU2210150020.SGD","LU1721428933.USD","IE00B64PRP62.GBP","BK4585","LU1165135440.EUR","MNQmain","LU0347712357.USD"],"gpt_icon":0},{"id":"2483287527","title":"Quince Therapeutics: Regains Compliance With Nasdaq Listing Rule 5450(a)(1)","url":"https://stock-news.laohu8.com/highlight/detail?id=2483287527","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483287527?lang=en_us&edition=fundamental","pubTime":"2024-11-14 19:58","pubTimestamp":1731585525,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241114:nFWN3ML0PM:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2483863650","title":"Quince Therapeutics Q3 EPS $(0.13) Up From $(0.15) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2483863650","media":"Benzinga","labels":["express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483863650?lang=en_us&edition=fundamental","pubTime":"2024-11-14 05:24","pubTimestamp":1731533058,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (NASDAQ:QNCX) reported quarterly losses of $(0.13) per share. This is a 13.33 percent increase over losses of $(0.15) per share from the same period last year.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/24/11/41955242/quince-therapeutics-q3-eps-0-13-up-from-0-15-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","QNCX"],"gpt_icon":0},{"id":"2483579600","title":"Quince Therapeutics presents data from prior Phase 3 ATTeST clinical trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2483579600","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2483579600?lang=en_us&edition=fundamental","pubTime":"2024-11-13 05:15","pubTimestamp":1731446157,"startTime":"0","endTime":"0","summary":"Quince Therapeutics (QNCX) “announced the presentation of two posters at the 2024 International Congress for Ataxia Research (ICAR) of data from it...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-presents-data-from-prior-phase-3-attest-clinical-trial?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-presents-data-from-prior-phase-3-attest-clinical-trial?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["LENZ","BK4139","QNCX"],"gpt_icon":0},{"id":"2482765841","title":"Quince Therapeutics Presents Safety Data From Prior Phase 3 Attest Clinical Trial at 53Rd Child Neurology Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482765841","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482765841?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359101,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241111:nTUA1MFWSG:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK4139","QNCX"],"gpt_icon":0},{"id":"2482658367","title":"Quince Therapeutics Presents Safety Data from Prior Phase 3 ATTeST Clinical Trial at 53rd Child Neurology Society Annual Meeting","url":"https://stock-news.laohu8.com/highlight/detail?id=2482658367","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482658367?lang=en_us&edition=fundamental","pubTime":"2024-11-12 05:05","pubTimestamp":1731359100,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., November 11, 2024----Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced the poster presentation at the 53rd Child Neurology Society  Annual Meeting of safety data from its prior Phase 3 ATTeST  clinical trial. The objective of the data analysis was to evaluate treatment-emergent adverse events  in patients with Ataxia-Telangiectasia (A-T) treated with the company’s lead asset, EryDex , for one year compared to placebo control.Key findings reported in the poster presentation, titled Treatment-Emergent Adverse Events  in Children With Ataxia-Telangiectasia Treated for One Year With Intra-Erythrocyte Dexamethasone Sodium Phosphate , include:. EryDex treatment was generally well tolerated with most TEAEs being mild to moderate and transient, and generally similar between EryDex- and placebo-treated patients.The Phase 3 NEAT trial is being ","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/.4gpwbEOwjMXPcRxtshgbA--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f0798fc6f95c1a2cd7f76e8c08b0a52","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/.4gpwbEOwjMXPcRxtshgbA--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/8f0798fc6f95c1a2cd7f76e8c08b0a52"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quince-therapeutics-presents-safety-data-210500823.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["CNS","QNCX","BK4585","DSP","MAA","BK4215","BK4135","LENZ","BK4139","SPA","BK4588","BK4023"],"gpt_icon":1},{"id":"2482146190","title":"Quince Therapeutics Inc  expected to post a loss of 10 cents a share - Earnings Preview","url":"https://stock-news.laohu8.com/highlight/detail?id=2482146190","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482146190?lang=en_us&edition=fundamental","pubTime":"2024-11-09 08:42","pubTimestamp":1731112939,"startTime":"0","endTime":"0","summary":"Quince Therapeutics Inc  expected to post a loss of10cents a share - Earnings Preview Quince Therapeutics Inc QNCX.OQ QNCX.O is expected to report resultson November 12 (estimated) for the period endi","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241109:nL8N3MG03Z:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX"],"gpt_icon":0},{"id":"2481077129","title":"Quince Therapeutics Initiated at Buy by Maxim Group","url":"https://stock-news.laohu8.com/highlight/detail?id=2481077129","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481077129?lang=en_us&edition=fundamental","pubTime":"2024-11-07 21:38","pubTimestamp":1730986680,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  November 07, 2024 08:38 ET (13:38 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["QNCX","LENZ","BK4139"],"gpt_icon":0},{"id":"2479728403","title":"Quince Therapeutics Initiated at Buy by Rodman & Renshaw","url":"https://stock-news.laohu8.com/highlight/detail?id=2479728403","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479728403?lang=en_us&edition=fundamental","pubTime":"2024-10-29 19:44","pubTimestamp":1730202240,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2024 07:44 ET (11:44 GMT)","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX","LENZ"],"gpt_icon":0},{"id":"2477387116","title":"Quince Therapeutics initiated with a Buy at EF Hutton","url":"https://stock-news.laohu8.com/highlight/detail?id=2477387116","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477387116?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:26","pubTimestamp":1729596364,"startTime":"0","endTime":"0","summary":"EF Hutton analyst Jason Kolbert initiated coverage of Quince Therapeutics (QNCX) with a Buy rating and $12 price target Quince is a biotechnology c...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-initiated-with-a-buy-at-ef-hutton?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/quince-therapeutics-initiated-with-a-buy-at-ef-hutton?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["QNCX","LENZ","BK4139"],"gpt_icon":0},{"id":"2477387440","title":"Quince Therapeutics Initiated at Buy by EF Hutton","url":"https://stock-news.laohu8.com/highlight/detail?id=2477387440","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2477387440?lang=en_us&edition=fundamental","pubTime":"2024-10-22 19:26","pubTimestamp":1729596360,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/QNCX/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 22, 2024 07:26 ET (11:26 GMT)","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LENZ","QNCX","BK4139"],"gpt_icon":0},{"id":"2475343317","title":"Quince Therapeutics to Participate at Upcoming Investor Conferences","url":"https://stock-news.laohu8.com/highlight/detail?id=2475343317","media":"Business Wire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2475343317?lang=en_us&edition=fundamental","pubTime":"2024-10-15 04:05","pubTimestamp":1728936300,"startTime":"0","endTime":"0","summary":"SOUTH SAN FRANCISCO, Calif., October 14, 2024----Quince Therapeutics, Inc. , a late-stage biotechnology company dedicated to unlocking the power of a patient’s own biology for the treatment of rare diseases, today announced that management will present at three upcoming investor conferences:. 2024 Maxim Healthcare Virtual Summit – Quince’s Chief Executive Officer and Chief Medical Officer Dirk Thye, M.D., will participate in a fireside chat on Thursday, October 17, 2024 beginning at 3:00 p.m. Eastern Time. Qualified investors can register here to access the live event.LD Micro Main Event XVII – Quince’s Chief Operating Officer and Chief Business Officer Brendan Hannah will present a company overview on Tuesday, October 29, 2024 beginning at 6:30 p.m. Eastern Time. Please register here to access the live presentation.The ThinkEquity Conference 2024 – Quince’s President Charles Ryan, J.D., Ph.D., will present a company overview on October 30, 2024 beginning at 3:00 p.m. Eastern Time. A w","market":"us","thumbnail":"https://s.yimg.com/uu/api/res/1.2/T66WgFE7t9.wDmH0_Iw5BQ--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d5d41e630a48c51b7264742f75aa2029","type":0,"news_type":0,"thumbnails":["https://s.yimg.com/uu/api/res/1.2/T66WgFE7t9.wDmH0_Iw5BQ--~B/aD00NDI7dz0xMTIxO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/business-wire.com/d5d41e630a48c51b7264742f75aa2029"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://finance.yahoo.com/news/quince-therapeutics-participate-upcoming-investor-200500491.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"yahoofinance","symbols":["QNCX","LENZ","BK4139"],"gpt_icon":0},{"id":"2460809049","title":"Quince Therapeutics: High-Potential Turnaround With Phase 3 Asset EryDex","url":"https://stock-news.laohu8.com/highlight/detail?id=2460809049","media":"seekingalpha","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2460809049?lang=en_us&edition=fundamental","pubTime":"2024-08-20 09:16","pubTimestamp":1724116601,"startTime":"0","endTime":"0","summary":"Quince’s transformation is complete with the acquisition of EryDel in October 2023.The ongoing Phase 3 trial for the orphan disease Ataxia-Telangiectasia builds on the recently published teachings of ","market":"us","thumbnail":"https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689003176/image_1689003176.jpg","type":0,"news_type":0,"thumbnails":["https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1689003176/image_1689003176.jpg"],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://seekingalpha.com/article/4715739-quince-therapeutics-high-potential-turnaround-with-phase-3-asset-erydex","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"seekingalpha","symbols":["BK4585","LENZ","LU0889565916.HKD","IE0009355771.USD","BK4568","BK4532","LU2065170008.USD","IE00BJT1NW94.SGD","IE00BFTCPJ56.SGD","SRPT","IE00B894F039.SGD","IE00B2B36J28.USD","BK4535","IE00BJJMRZ35.SGD","LU0109394709.USD","BK4533","LU2065171311.SGD","LU0320765992.SGD","IE00B19Z9Z06.USD","INMB","IE0002141913.USD","BK4588","IE00B19Z9P08.USD","QNCX","LU2065169927.USD","ACAD","BIIB","CDTX","LU2065171402.SGD","BK4139","VIR","LU0234570918.USD"],"gpt_icon":0},{"id":"2459744762","title":"BRIEF-Quince Therapeutics Announces The Lancet Neurology Publication Of Phase 3 ATTeST Clinical Trial Data Evaluating Erydex","url":"https://stock-news.laohu8.com/highlight/detail?id=2459744762","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2459744762?lang=en_us&edition=fundamental","pubTime":"2024-08-15 19:04","pubTimestamp":1723719852,"startTime":"0","endTime":"0","summary":"Aug 15  - Quince Therapeutics Inc   :   * QUINCE THERAPEUTICS ANNOUNCES THE LANCET NEUROLOGY PUBLICATION OF PHASE 3 ATTEST CLINICAL TRIAL DATA EVALUATING ERYDEX FOR THE TREATMENT OF ATAXIA-TELANGIECTASIA (A-T)   * QUINCE THERAPEUTICS: EXPECTS TO REPORT TOPLINE RESULTS IN Q4 OF 2025   * QUINCE THERAPEUTICS: EXPECTS POTENTIAL NDA SUBMISSION TO FDA & MARKETING AUTHORIZATION APPLICATION SUBMISSION TO EMA IN 2026Source text for Eikon:    Further company coverage:    ","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://api.rkd.refinitiv.com/api/News/News.svc/REST/News_1/RetrieveStoryML_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","QNCX","LENZ"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.quincetx.com","stockEarnings":[{"period":"1week","weight":-0.1232},{"period":"1month","weight":-0.0326},{"period":"3month","weight":1.0571},{"period":"6month","weight":1.5429},{"period":"1year","weight":0.633},{"period":"ytd","weight":0.6952}],"compareEarnings":[{"period":"1week","weight":-0.0216},{"period":"1month","weight":0.0011},{"period":"3month","weight":0.0403},{"period":"6month","weight":0.0857},{"period":"1year","weight":0.2506},{"period":"ytd","weight":0.2437}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"Quince Therapeutics, Inc., a preclinical stage biopharmaceutical company, develops precision therapeutics for debilitating and rare diseases. Its lead compound is NOV004, a systemically administered bone anabolic peptide engineered to target and concentrate at bone fracture sites. The company was formerly known as Cortexyme, Inc. and changed its name to Quince Therapeutics, Inc. in August 2022. Quince Therapeutics, Inc. was incorporated in 2012 and is headquartered in South San Francisco, California.","yearOnYearQuotes":[{"month":1,"riseRate":0.6,"avgChangeRate":0.089809},{"month":2,"riseRate":0.4,"avgChangeRate":-0.070311},{"month":3,"riseRate":0.6,"avgChangeRate":0.177065},{"month":4,"riseRate":0.6,"avgChangeRate":-0.06623},{"month":5,"riseRate":0.4,"avgChangeRate":-0.093958},{"month":6,"riseRate":0.666667,"avgChangeRate":0.117631},{"month":7,"riseRate":0.166667,"avgChangeRate":-0.094125},{"month":8,"riseRate":0.5,"avgChangeRate":0.047322},{"month":9,"riseRate":0.5,"avgChangeRate":0.013137},{"month":10,"riseRate":0.166667,"avgChangeRate":-0.05998},{"month":11,"riseRate":0.5,"avgChangeRate":0.030681},{"month":12,"riseRate":0.333333,"avgChangeRate":0.09887}],"exchange":"NASDAQ","name":"Quince Therapeutics, Inc.","nameEN":"Quince Therapeutics, Inc."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.29.3","shortVersion":"4.29.3","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"Quince Therapeutics, Inc.,QNCX,Quince Therapeutics, Inc.股票,Quince Therapeutics, Inc.股票老虎,Quince Therapeutics, Inc.股票老虎国际,Quince Therapeutics, Inc.行情,Quince Therapeutics, Inc.股票行情,Quince Therapeutics, Inc.股价,Quince Therapeutics, Inc.股市,Quince Therapeutics, Inc.股票价格,Quince Therapeutics, Inc.股票交易,Quince Therapeutics, Inc.股票购买,Quince Therapeutics, Inc.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"Quince Therapeutics, Inc.(QNCX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest Quince Therapeutics, Inc.(QNCX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}

Introduction